Please try another search
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Yoshikazu Nakamura | 77 | 2005 | President & Representative Director |
Yutaka Yabe | 81 | 2010 | Outside Auditor |
Karl G. Csaky | - | 2018 | Member of Scientific Advisory Board |
Toshiaki Nishihata | 76 | 2016 | Independent Outside Director |
Hisato Oiwa | 66 | - | Executive Officer, GM of Management Headquarters & Director |
Yasuhiro Fujii | 46 | 2018 | Independent Outside Auditor |
Pavel Krejcí | - | - | Member of Scientific Advisory Board |
Rajendra Apte | - | - | Member of Scientific Advisory Board |
Robert B. Bhisitkul | - | - | Member of Scientific Advisory Board |
Senya Matsufuji | 66 | 2021 | Independent Outside Director |
Akiyuki Igarashi | 68 | 2023 | Independent Auditor |
Toshinobu Fujiwara | 52 | 2023 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review